Lexeo Therapeutics, Inc.

Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Current securities

1. Entry into a Material Definitive Agreement · Other EventsSep 22, 2026
2. 144 filingAug 18, 2026
3. 10-Q filingAug 12, 2026
4. Results of Operations and Financial Condition · Other EventsAug 12, 2026
5. 144 filingJul 1, 2026